Navigation Links
China Biologic Products to Ring NASDAQ Opening Bell
Date:12/10/2009

TAI'AN, China, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based biopharmaceutical companies in China, today announced that the Company's senior management team will ring the opening bell at the NASDAQ MarketSite in New York City at 9:30 a.m. ET on Tuesday, December 15, 2009.

China Biologic's common stock began trading on the NASDAQ Global Market on December 2, 2009, under the ticker symbol "CBPO."

"We are honored to ring the NASDAQ opening bell to celebrate our listing on one of the most prestigious equity markets in the world," said Mr. Chao Ming Zhao, China Biologic's Chief Executive Officer. "We would like to thank our shareholders, dedicated employees, board of directors, management team, and all other parties who have contributed to our success to date."

A live webcast of the NASDAQ Opening Bell (starting from 9:20 a.m. ET) will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. For more information please visit the Company's website http://www.chinabiologic.com .

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the significance of the Company's listing on the NASDAQ Global Market; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:   http://www.chinabiologic.com

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Athan Dounis, Account Manager
     Tel:   +1-646-213-1916
     Email: athan.dounis@ccgir.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Biologic Products, Inc.


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
2. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
3. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
4. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
5. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
6. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
7. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
8. Niusule Expands Geographic Footprint in China
9. China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference
10. China Business Knowledge Launches “China Prospects Forum” -- Dec. 9, 2009, New York City
11. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter Fiscal 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... WASHINGTON , Feb. 11, 2016   BioInformant ... strategic report, "Stem Cell Research Products, Opportunities, Tools, and ... 2020. ... specialize in the stem cell industry, BioInformant has more ... of the stem cell market, by stem cell type. ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
(Date:2/10/2016)... Md. , Feb. 10, 2016  The Maryland ... Busch , has announced that University of Maryland School ... PhD, MBA and University of Maryland Medical System President ... of the "Speaker,s Medallion," the highest honor given to ... of Delegates. Dean Reece and Mr. ...
(Date:2/10/2016)... and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined ... new vaccines and immunotherapies for infectious diseases and cancer. , The ...
Breaking Biology Technology:
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
Breaking Biology News(10 mins):